Thursday, April 17, 2014

Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology

 2014 Apr 15. [Epub ahead of print]

Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.



The financial implications of the 340B discount can be significant for a health care institution. The discount can substantially reduce the burden on covered entities that provide uncompensated or undercompensated care. In addition, drugs purchased by the covered entity at a discount can be sold to all individuals who meet the program's definition of a “patient.” 

No comments:

Post a Comment